Global Sangers Sequencing Service Market Size, Share, Analysis Report - Forecast 2032

Sangers Sequencing Service Market Insights

According to Market Research Store, the global sangers sequencing service market size was valued at around USD 582.68 million in 2023 and is estimated to reach USD 1135.98 million by 2032, to register a CAGR of approximately 7.7% in terms of revenue during the forecast period 2024-2032.

The sangers sequencing service report provides a comprehensive analysis of the market, including its size, share, growth trends, revenue details, and other crucial information regarding the target market. It also covers the drivers, restraints, opportunities, and challenges till 2032.

To Get more Insights, Request a Free Sample

Global Sangers Sequencing Service Market: Overview

Sangers sequencing service refers to the professional offering of DNA sequencing based on the Sanger method, a widely used and highly accurate technique for determining the nucleotide sequence of DNA. Also known as chain termination sequencing, the Sanger method utilizes labeled dideoxynucleotides (ddNTPs) to terminate DNA strand elongation during polymerase chain reactions. The resulting DNA fragments of varying lengths are then separated via capillary electrophoresis, and the sequence is determined based on the fluorescent labels of the terminated fragments.

Sangers sequencing services are widely used in research institutions, clinical diagnostics, biotechnology firms, and academic laboratories for applications requiring high accuracy over relatively short read lengths, typically up to 900 base pairs. Common applications include plasmid verification, mutation detection, small-scale genome mapping, and validation of next-generation sequencing (NGS) results. Despite the growing adoption of NGS for high-throughput sequencing needs, Sanger sequencing remains the gold standard for its reliability, simplicity, and cost-effectiveness in targeted sequencing tasks.

Key Highlights

• The sangers sequencing service market is anticipated to grow at a CAGR of 7.7% during the forecast period.
• The global sangers sequencing service market was estimated to be worth approximately USD 582.68 million in 2023 and is projected to reach a value of USD 1135.98 million by 2032.
• The growth of the sangers sequencing service market is being driven by the escalating demand for genetic testing and personalized medicine, alongside its crucial role in clinical diagnostics and research.
• Based on the application, the diagnostics segment is growing at a high rate and is projected to dominate the market.
• On the basis of end user, the academic & government research institutes segment is projected to swipe the largest market share.
• By region, North America is expected to dominate the global market during the forecast period.

Sangers Sequencing Service Market: Dynamics

Key Growth Drivers:

• Continued Need for Validation of NGS Data: Despite the high throughput of NGS, Sanger sequencing remains the "gold standard" for validating specific variants or regions identified by NGS, particularly in clinical diagnostics and research where high accuracy is paramount.
• Targeted Sequencing of Shorter DNA Fragments: For sequencing single genes, specific gene regions (e.g., PCR products, plasmid DNA), or small amplicons (up to ~1000 bp), Sanger sequencing offers high accuracy and cost-effectiveness compared to running an entire NGS experiment.
• Increasing Applications in Clinical Diagnostics: Sanger sequencing is crucial for diagnosing specific genetic disorders, confirming mutations, detecting cancer biomarkers, and in newborn screening programs due to its high accuracy and reliability for targeted analysis.
• Growth in Personalized Medicine and Pharmacogenomics: As personalized medicine gains traction, the need for precise genetic testing to guide treatment decisions and predict drug responses (pharmacogenomics) drives demand for Sanger sequencing services.
• Ongoing Research and Development in Genomics: Academic and government research institutes, as well as pharmaceutical and biotechnology companies, continue to utilize Sanger sequencing for various research applications, including gene expression profiling, genetic variation analysis, and drug discovery.
• Cost-Effectiveness for Small-Scale Projects: For projects involving a limited number of samples or specific genes, Sanger sequencing can be more cost-effective than setting up and running high-throughput NGS platforms.
• Advancements in Automation and Bioinformatics Tools: Improved automation in sequencing systems and sophisticated bioinformatics tools for data analysis enhance the efficiency and accessibility of Sanger sequencing services.

Restraints:

• Competition from Next-Generation Sequencing (NGS) Technologies: NGS offers significantly higher throughput and lower cost per base for large-scale genomic projects (whole-genome, whole-exome sequencing), which limits Sanger's applicability in such broad analyses.
• Limited Throughput and Slower Processing Times: Sanger sequencing is inherently a lower-throughput method compared to NGS, making it less suitable for applications requiring the sequencing of millions of DNA fragments simultaneously or rapid turnaround for large datasets.
• Higher Cost per Base for Large Projects: While cost-effective for small-scale, targeted sequencing, the cost per base for Sanger sequencing becomes prohibitive when dealing with large genomic regions or high volumes of samples.
• Limitations in Detecting Novel Variants in Large Regions: Sanger sequencing is primarily a targeted approach; it is not designed for comprehensive discovery of novel variants across vast genomic regions, which is an advantage of NGS.
• Potential for Quality Degradation at Read Ends: The quality of Sanger sequences can degrade at the initial (primer binding) and latter (after 700-900 bases) ends of the read, potentially requiring multiple reads or specific strategies for complete coverage.
• Requirement for Skilled Personnel for Data Interpretation (in complex cases): While automated, interpreting complex Sanger sequencing data, especially for heterozygotes or challenging regions, still requires skilled personnel.

Opportunities:

• Integration with NGS Workflows for Confirmation: The synergistic use of Sanger sequencing to confirm critical NGS findings, particularly in clinical and diagnostic settings, presents a strong and persistent opportunity.
• Specialized Applications in Forensics and Microbial Identification: Its high accuracy for short reads makes Sanger sequencing valuable in forensics for STR analysis and in clinical microbiology for precise pathogen identification and subtyping.
• Growth in Reproductive Health Screening: Applications in non-invasive prenatal testing (NIPT) confirmation and preimplantation genetic testing (PGT) contribute to demand for accurate targeted sequencing.
• Expansion in Developing Economies: As healthcare infrastructure and genomic research grow in emerging markets, the demand for reliable and relatively straightforward sequencing services like Sanger is expected to increase.
• Focus on Custom Sequencing Solutions: Service providers can offer highly customized Sanger sequencing solutions for unique research challenges or specific diagnostic panels.
• Use in Gene Editing (CRISPR) Validation: Sanger sequencing is a critical tool for validating the success and specificity of gene editing experiments, such as CRISPR-Cas9, by confirming changes at targeted genomic loci.
• Applications in Agricultural Genomics: For targeted gene analysis in crop improvement, disease resistance, and genetic characterization of plants and animals.

Challenges:

• Staying Relevant Amidst NGS Dominance: The primary challenge is to clearly define and communicate the unique value proposition of Sanger sequencing services in a market increasingly dominated by NGS technologies.
• Managing Data Analysis and Interpretation for Specific Needs: While data volume is lower than NGS, the precise interpretation of Sanger data for diagnostics or specific research questions can still be complex.
• Technological Improvements to Remain Competitive: Continuous efforts are needed to enhance automation, improve turnaround times, and potentially lower costs for specific Sanger applications to maintain competitiveness.
• Quality Control and Accuracy Maintenance: Ensuring consistent, high-quality sequence data and maintaining the renowned accuracy that is the hallmark of Sanger sequencing.
• Addressing the Skills Gap in Bioinformatics (for downstream analysis): Even for Sanger, effective utilization often requires bioinformatics skills for primer design, sequence alignment, and variant calling.
• Impact of Decreasing Costs of NGS: While Sanger has its niche, the continued reduction in NGS costs could put pressure on the pricing and perceived value of Sanger services for certain applications.
• Regulatory Scrutiny for Diagnostic Use: As Sanger sequencing is used in clinical diagnostics, it faces stringent regulatory requirements for validation and accreditation, which can be challenging to meet and maintain.

Sangers Sequencing Service Market: Report Scope

This report thoroughly analyzes the Sangers Sequencing Service Market, exploring its historical trends, current state, and future projections. The market estimates presented result from a robust research methodology, incorporating primary research, secondary sources, and expert opinions. These estimates are influenced by the prevailing market dynamics as well as key economic, social, and political factors. Furthermore, the report considers the impact of regulations, government expenditures, and advancements in research and development on the market. Both positive and negative shifts are evaluated to ensure a comprehensive and accurate market outlook.

Sangers Sequencing Service Market: Segmentation Insights

The global sangers sequencing service market is divided by application, end user, and region.

Segmentation Insights by Application

Based on application, the global sangers sequencing service market is divided into diagnostics, biomarkers & cancer, reproductive health, personalized medicine, forensics, and others.

Diagnostics remains the dominate and most mature application segment in the Sangers sequencing services market. This segment includes genetic testing for monogenic diseases, infectious disease identification, and rare disorder confirmation. Sanger sequencing's high accuracy and reliability in reading nucleotide sequences make it ideal for confirming mutations detected through high-throughput methods. It is also heavily relied upon in clinical laboratories for validating new gene variants, minimizing false positives, and ensuring precision in clinical decisions. With regulatory bodies such as the FDA and EMA recognizing Sanger sequencing as a confirmatory tool, its use in diagnostics is expected to remain stable.

Biomarkers & Cancer is a rapidly growing segment driven by the rising demand for precision oncology. In cancer research and diagnostics, Sanger sequencing is widely employed to confirm specific mutations in genes such as BRCA1/2, EGFR, KRAS, and TP53. This application is crucial for targeted therapy selection and prognosis evaluation. Additionally, Sanger sequencing plays a role in identifying novel tumor markers and validating those discovered through NGS and other omics platforms. Pharmaceutical companies and research institutions increasingly depend on Sanger sequencing to support drug development, biomarker validation, and translational research programs.

Reproductive Health is a vital segment, encompassing applications in prenatal testing, carrier screening, and preimplantation genetic diagnosis (PGD). Sanger sequencing is instrumental in confirming genetic abnormalities such as aneuploidies, single-gene disorders, and structural variations that impact embryo viability and fetal development. Its role is particularly critical in assisted reproductive technologies (ART), where decisions regarding embryo implantation rely on accurate genetic screening. As demand for fertility treatments and prenatal genetic counseling rises, so too does the reliance on Sanger sequencing for precision and cost-effectiveness.

Personalized Medicine is gaining significant traction as healthcare shifts toward individualized treatment strategies. Sanger sequencing supports this trend by providing accurate confirmation of patient-specific genetic variants used to tailor drug selection and dosage. It is frequently used in pharmacogenomic testing, where it helps assess how individual genetic differences affect responses to drugs. This enhances treatment outcomes and minimizes adverse drug reactions. Though next-generation sequencing dominates broader applications, Sanger sequencing is preferred for small-scale, targeted gene validation due to its affordability and robustness.

Forensics remains a specialized but critical application of Sanger sequencing. Law enforcement agencies and forensic laboratories utilize this technique for generating DNA profiles in criminal cases, missing person identification, and paternity disputes. It is highly valued for its ability to produce high-fidelity, legally admissible DNA results from degraded or limited biological samples. In addition to human identification, Sanger sequencing is also applied in wildlife forensics and biodiversity assessments. The segment benefits from technological advancements that enable rapid analysis while maintaining the chain of custody and data integrity.

Segmentation Insights by End User

On the basis of end user, the global sangers sequencing service market is bifurcated into academic & government research institutes, pharmaceutical companies, biotechnology companies, and hospitals & clinics.

Academic & Government Research Institutes represent the dominant end-user segment in the Sangers sequencing service market. These institutions rely heavily on Sanger sequencing for fundamental and applied research due to its high accuracy, reliability, and cost-effectiveness for small-scale projects. It remains a preferred method for gene validation, mutational analysis, and microbial identification in academic laboratories. Government-funded genomics projects and national health research programs also drive substantial demand in this segment, especially across areas such as plant genetics, animal studies, and pathogen surveillance. These organizations often utilize centralized sequencing facilities or partner with commercial service providers to conduct high volumes of targeted sequencing. The growing number of research grants, international collaborations, and focus on genetic databases further strengthens the position of this segment as the primary driver of market revenue.

Pharmaceutical Companies extensively use Sanger sequencing in drug discovery, clinical development, and biomarker validation. It serves as a critical tool in identifying genetic mutations associated with diseases, confirming gene edits in CRISPR applications, and validating results from broader genomic screening methods. The high specificity of Sanger sequencing is particularly important in Good Laboratory Practice (GLP)-compliant environments and regulatory submissions, especially when sequencing is required for investigational new drug (IND) applications. Its use in pharmacogenomics and personalized medicine research is also driving growth within this segment.

Biotechnology Companies represent a rapidly expanding user base for Sanger sequencing services. These firms engage in developing innovative diagnostics, gene therapies, agricultural biotech products, and synthetic biology applications. Sanger sequencing supports quality control, sequence validation, and construct verification in genetic engineering workflows. Small and mid-sized biotech companies often outsource sequencing tasks to service providers due to the cost and complexity of maintaining in-house platforms, making them a critical driver of the service-based Sanger sequencing market.

Hospitals & Clinics use Sanger sequencing primarily for clinical diagnostics and patient management. This includes applications in hereditary disease screening, oncology, infectious disease identification, and prenatal genetic testing. The method’s high reliability in confirming genetic variants discovered through broader panels (e.g., NGS or microarrays) makes it essential in routine clinical workflows. With the increasing integration of genetic testing into personalized treatment plans, the demand from hospitals and specialty clinics is expected to rise steadily. This segment also benefits from the growing adoption of genetic counseling and precision medicine initiatives.

Sangers Sequencing Service Market: Regional Insights

• North America is expected to dominate the global market

North America dominates the Sangers Sequencing Service Market due to its advanced genomic infrastructure, strong presence of leading biotechnology firms, and robust funding for life sciences research. The United States is the primary contributor, driven by high academic and clinical demand for DNA sequencing in areas such as oncology, genetic disorders, and microbial identification. Major players, including Thermo Fisher Scientific and Eurofins Scientific, have established expansive service networks and customized sequencing solutions for both small-scale research and high-throughput clinical applications. Additionally, the growing demand for precision medicine and regulatory support for genetic testing further propels market growth in the region. Canada also shows steady adoption, with an emphasis on agricultural genomics and population-wide sequencing studies.

Europe holds a significant share of the global Sanger Sequencing Service Market, with countries like Germany, the UK, and France leading the regional landscape. The presence of strong academic research institutions, pharmaceutical R&D centers, and government-sponsored genomics programs boosts market performance. Germany, for instance, is a key hub for molecular diagnostics and clinical sequencing, while the UK benefits from national initiatives like Genomics England. The region sees high demand for Sanger sequencing in confirmatory testing, gene editing validation, and hereditary disease diagnostics. Furthermore, European laboratories emphasize accuracy and traceability, making Sanger sequencing a preferred method for clinical-grade validation.

Asia-Pacific is witnessing rapid growth in the Sanger Sequencing Service Market, driven by increased research funding, growing biotechnology sectors, and rising awareness of genetic testing. China and India are at the forefront, supported by expanding genomic research initiatives, investments in molecular diagnostics, and increasing partnerships with global sequencing firms. In Japan and South Korea, government-backed precision medicine programs and strong academic infrastructure fuel consistent demand for accurate sequencing services. Sanger sequencing remains widely used for validation and quality assurance in next-generation sequencing workflows across research institutes and diagnostic labs in the region.

Latin America is emerging as a developing market for Sanger sequencing services, led by Brazil, Mexico, and Argentina. Brazil's growing life sciences sector and increasing adoption of genetic testing for rare diseases and oncology diagnostics are fueling demand for reliable sequencing services. Mexico is focusing on enhancing its molecular diagnostic capabilities, especially in academic and clinical laboratories. Although adoption is slower compared to other regions due to cost constraints and limited infrastructure, regional partnerships and technology transfers are expanding access to sequencing services, particularly in public health and agricultural research.

Middle East and Africa show gradual uptake in the Sanger Sequencing Service Market, mainly in the Gulf Cooperation Council (GCC) countries and South Africa. In the UAE and Saudi Arabia, increasing investments in healthcare innovation and genomic medicine are fostering demand for sequencing solutions. Clinical labs and research institutions are incorporating Sanger sequencing for mutation confirmation and pathogen identification. In Africa, South Africa is the leading country adopting these services, especially for academic research and infectious disease studies. However, challenges such as limited infrastructure and cost barriers persist in many parts of the region, though international collaborations are helping bridge the gap.

Sangers Sequencing Service Market: Competitive Landscape

The report provides an in-depth analysis of companies operating in the sangers sequencing service market, including their geographic presence, business strategies, product offerings, market share, and recent developments. This analysis helps to understand market competition.

Some of the major players in the global sangers sequencing service market include:

• Source BioScience
• Quintara Biosciences
• Laragen
• StarSEQ
• Nucleics Pty. Ltd.
• Fasteris SA
• Genscript Biotech Corporation
• GenHunter Corporation
• SciGenom Labs Pvt. Ltd.
• Thermo Fisher Scientific Inc.
• CeMIA SA
• LGC Science Group Holdings Limited
• Microsynth AG
• GENEWIZ Inc.

The global sangers sequencing service market is segmented as follows:

By Application

• Diagnostics
• Biomarkers & Cancer
• Reproductive Health
• Personalized Medicine
• Forensics
• Others

By End User

• Academic & Government Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Hospitals & Clinics

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• The Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East Africa

Frequently Asked Questions